Distinct cerebrospinal fluid amyloid peptide signatures in sporadic and PSEN1 A431E-associated familial Alzheimer's disease

Molecular Neurodegeneration

Volumn 5, Issue 1, 2010, Pages

  Portelius, Erik ^a   Andreasson, Ulf ^a   Ringman, John M ^b   Buerger, Katharina ^c   Daborg, Jonny ^a   Buchhave, Peder ^d   Hansson, Oskar ^d   Harmsen, Andreas ^a   Gustavsson, Mikael K ^a   Hanse, Eric ^a   Galasko, Douglas ^e   Hampel, Harald ^c,f,g   Blennow, Kaj ^a   Zetterberg, Henrik ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MUNICH   (Germany)

^d LUND UNIVERSITY   (Sweden)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TRINITY COLLEGE DUBLIN   (Ireland)

^g ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID BETA PROTEIN[25-35]; GAMMA SECRETASE; PRESENILIN 1;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; FAMILIAL ALZHEIMER DISEASE; FAMILIAL DISEASE; FEMALE; GENE MUTATION; HUMAN; IMMUNOPRECIPITATION; MALE; MASS SPECTROMETRY; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN CLEAVAGE; SPORADIC ALZHEIMER DISEASE;

EID: 76749167709     PISSN: None     EISSN: 17501326     Source Type: Journal    
DOI: 10.1186/1750-1326-5-2     Document Type: Article

References (33)

1. Alzheimer's disease. K Blennow MJ de Leon H Zetterberg, Lancet 2006 368 387 403 10.1016/S0140-6736(06)69113-7 16876668
2. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. H Hampel K Burger SJ Teipel AL Bokde H Zetterberg K Blennow, Alzheimers Dement 2008 4 38 48 10.1016/j.jalz.2007.08.006 18631949
3. CSF markers for incipient Alzheimer's disease. K Blennow H Hampel, Lancet Neurol 2003 2 605 613 10.1016/S1474-4422(03)00530-1 14505582
4. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. D Strozyk K Blennow LR White LJ Launer, Neurology 2003 60 652 656 12601108
5. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. AM Fagan MA Mintun RH Mach SY Lee CS Dence AR Shah GN LaRossa ML Spinner WE Klunk CA Mathis ST DeKosky JC Morris DM Holtzman, Ann Neurol 2006 59 512 519 10.1002/ana.20730 16372280
6. PET imaging of amyloid deposition in patients with mild cognitive impairment. A Forsberg H Engler O Almkvist G Blomquist G Hagman A Wall A Ringheim B Långström A Nordberg, Neurobiol Aging 2008 29 1456 1465 10.1016/j.neurobiolaging.2007.03.029 17499392
7. Aspects of beta-amyloid as a biomarker for Alzheimer's disease. U Andreasson E Portelius ME Andersson K Blennow H Zetterberg, Biomarkers Med 2007 1 59 78 10.2217/17520363.1.1.59
8. Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. I Klyubin V Betts AT Welzel K Blennow H Zetterberg A Wallin CA Lemere WK Cullen Y Peng T Wisniewski DJ Selkoe R Anwyl DM Walsh MJ Rowan, J Neurosci 2008 28 4231 4237 10.1523/JNEUROSCI.5161-07.2008 18417702
9. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. GM Shankar BL Bloodgood M Townsend DM Walsh DJ Selkoe BL Sabatini, J Neurosci 2007 27 2866 2875 10.1523/JNEUROSCI.4970-06.2007 17360908
10. Alzheimer's disease: genes, proteins, and therapy. DJ Selkoe, Physiol Rev 2001 81 741 766 11274343
11. Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. M Bentahir O Nyabi J Verhamme A Tolia K Horré J Wiltfang H Esselmann B De Strooper, J Neurochem 2006 96 732 742 10.1111/j.1471-4159.2005.03578.x 16405513
12. Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40. S Kumar-Singh J Theuns B Van Broeck D Pirici K Vennekens E Corsmit M Cruts B Dermaut R Wang C Van Broeckhoven, Hum Mutat 2006 27 686 695 10.1002/humu.20336 16752394
13. Targeted proteomics in Alzheimer's disease: focus on amyloid-beta. E Portelius H Zetterberg J Gobom U Andreasson K Blennow, Expert Rev Proteomics 2008 5 225 237 10.1586/14789450.5.2.225 18466053
14. Determination of beta-amyloid peptide signatures in cerebrospinal fluid using immunoprecipitation-mass spectrometry. E Portelius A Westman-Brinkmalm H Zetterberg K Blennow, J Proteome Res 2006 5 1010 1016 10.1021/pr050475v 16602710
15. Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. E Portelius AJ Tran U Andreasson R Persson G Brinkmalm H Zetterberg K Blennow A Westman-Brinkmalm, J Proteome Res 2007 6 4433 4439 10.1021/pr0703627 17927230
16. An Alzheimer's disease-specific beta-amyloid fragment signature in cerebrospinal fluid. E Portelius H Zetterberg U Andreasson G Brinkmalm N Andreasen A Wallin A Westman-Brinkmalm K Blennow, Neurosci Lett 2006 409 215 219 10.1016/j.neulet.2006.09.044 17049739
17. Founder effect for the Ala431Glu mutation of the presenilin 1 gene causing early-onset Alzheimer's disease in Mexican families. P Yescas A Huertas-Vazquez MT Villarreal-Molina A Rasmussen MT Tusié-Luna M Lápez S Canizales-Quinteros ME Alonso, Neurogenetics 2006 7 195 200 10.1007/s10048-006-0043-3 16628450
18. The A431E mutation in PSEN1 causing familial Alzheimer's disease originating in Jalisco State, Mexico: an additional fifteen families. J Murrell B Ghetti E Cochran MA Macias-Islas L Medina A Varpetian JL Cummings MF Mendez C Kawas H Chui JM Ringman, Neurogenetics 2006 7 277 279 10.1007/s10048-006-0053-1 16897084
19. A novel mutation in the Presenilin-1 gene (A431E) associated with early-onset Alzheimer's disease. EJ Cochran JR Murrell J Fox J Ringman B Ghetti, J Exp Neuropathol Exp Neurol 2001 60 544
20. Biochemical markers in persons with preclinical familial Alzheimer disease. JM Ringman SG Younkin D Pratico W Seltzer GM Cole DH Geschwind Y Rodriguez-Agudelo B Schaffer J Fein S Sokolow ER Rosario KH Gylys A Varpetian LD Medina JL Cummings, Neurology 2008 71 85 92 10.1212/01.wnl.0000303973.71803.81 18509095
21. Amyloid-related biomarkers for Alzheimer's disease. N Andreasen H Zetterberg, Curr Med Chem 2008 15 766 771 10.2174/092986708783955572 18393845
22. A novel pathway for amyloid precursor protein processing. E Portelius E Price G Brinkmalm M Stiteler M Olsson R Persson A Westman-Brinkmalm H Zetterberg AJ Simon K Blennow, Neurobiol Aging 2009 doi:10.1016/j.neurobiolaging.2009.06. 002; PMID: 19604603
23. The ratio of monomeric to aggregated forms of Abeta40 and Abeta42 is an important determinant of amyloid-beta aggregation, fibrillogenesis, and toxicity. A Jan O Gokce R Luthi-Carter HA Lashuel, J Biol Chem 2008 283 28176 28189 10.1074/jbc.M803159200 18694930
24. Amyloid beta protein: Abeta40 inhibits Abeta42 oligomerization. MM Murray SL Bernstein V Nyugen MM Condron DB Teplow MT Bowers, J Am Chem Soc 2009 131 6316 6317 10.1021/ja8092604 19385598
25. Synaptic retrogenesis and amyloid-beta in Alzheimer's disease. P Wasling J Daborg I Riebe M Andersson E Portelius K Blennow E Hanse H Zetterberg, J Alzheimers Dis 2009 16 1 14 19158416
26. Variable phenotype of Alzheimer's disease with spastic paraparesis. H Karlstrom WS Brooks JB Kwok GA Broe JJ Kril H McCann GM Halliday PR Schofield, J Neurochem 2008 104 573 583 17995932
27. American Psychiatric Association, Diagnostic and statistical manual of mental disorders, third edition, revised Arlington, VA, USA: American Psychiatric Association 1987
28. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. G McKhann D Drachman M Folstein R Katzman D Price EM Stadlan, Neurology 1984 34 939 944 6610841
29. Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. JC Morris, Int Psychogeriatr 1997 9 Suppl 1 173 176 discussion 177-178 10.1017/S1041610297004870 9447441
30. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. MF Folstein SE Folstein PR McHugh, J Psychiatr Res 1975 12 189 198 10.1016/0022-3956(75)90026-6 1202204
31. Globular amyloid beta-peptide oligomer - a homogenous and stable neuropathological protein in Alzheimer's disease. S Barghorn V Nimmrich A Striebinger C Krantz P Keller B Janson M Bahr M Schmidt RS Bitner J Harlan E Barlow U Ebert H Hillen, J Neurochem 2005 95 834 847 10.1111/j.1471-4159.2005. 03407.x 16135089
32. OPLS discriminant analysis: combining the strengths of PLS-DA and SIMCA classification. M Bylesjö M Rantalainen O Cloarec J Nicholson E Holmes J Trygg, J Chemometrics 2007 20 341 351 10.1002/cem.1006
33. L Eriksson E Johansson N Kettaneh-Wold J Trygg C Wikström S Wold, Multi- and Megavariate Data Analysis Part I: Basic Principles and Applications, Second revised and enlarged edition Umeå: Umetrics AB 2006